A common feature of human breast oncogenesis is cell cycle deregulation. The expression of cyclin D1 and D3 was examined during estradiol-17β (E 2 )-induced mammary tumorigenesis in female ACI rats. Low serum E 2 levels (~60-120 pg/ml) were sufficient to induce mammary gland tumors (MGTs) that remarkably resemble human ductal breast cancer (BC) at the histopathologic and molecular levels. Western blot analysis of the E 2 -induced MGTs revealed a marked rise in cyclin D1 (24.0-fold), D3 (9.0-fold), and cdk4 (3.0-fold) expression compared to age-matched untreated controls.
Introduction
Breast cancer (BC) is the most prevalent cancer afflicting women in developed countries with sporadic (non-familial) BC comprising >90% of all cases [1] . One million new cases are reported worldwide each year [2] . Based on epidemiologic and animal studies, it is evident that estrogen, both endogenous and exogenous, is the major risk factor for this disease [2] [3] [4] . While estrogen clearly plays an important role in BC growth and progression, less is known about its involvement in BC causation.
Mammary gland tumors (MGTs) induced in female August Copenhagen Irish (ACI) rats by estradiol-17β (E 2 ), at low serum E 2 levels [5] , have emerged as arguably the most germane animal model for studying human sporadic BC since it shares many salient histopathologic and molecular features, both in early pre-malignant lesions and in primary tumors [6, 7] . For example, both human and the E 2 -induced murine breast neoplasms and their ductal carcinoma in-situ (DCISs) exhibit high frequencies of cmyc/Myc and Aurora A (AurA) over-expression, centrosome amplification [6] , chromosomal instability, c-myc amplification, and aneuploidy [6, 7] presumably via deregulation of specific cell cycle entities. Aneuploidy, a common feature of solid tumors, is the most defining characteristic of sporadic (DCIS) and invasive ductal BC, both human and E 2 -induced ACI rat breast (65-92%) [7] [8] [9] .
In human BC, MYC is over-expressed, and subsequently activates downstream cell cycle regulatory targets, including cyclins and their respective cyclin dependent kinases (cdks) [10, 11] . Three isoforms, D1, D2, and D3, comprise the cyclin D family, each of which binds and activates either cdk 4 or 6 [12] [13] [14] . In human breast tumors, cyclin D2 also binds cdk2 [15] .
The D cyclins hyperphosphorylate retinoblastoma (Rb) protein, resulting in the release of E2F transcription factor, hence conferring a growth advantage to estrogensusceptible breast cells when these proteins are over-expressed [16] . One of the downstream targets of E2F-mediated transcription is cyclin E1 that, when bound to cdk2, maintains the phosphorylation of Rb. In addition, active cyclin D1-cdk4/6 complexes sequester p21 and p27, and therefore, contribute to the sustained activation of the cyclin E1-cdk2 complexes [17] . Aberrant expression of cyclin D1 has been welldocumented in human BC [18] . Cyclin D1 mRNA and protein are frequently overexpressed in breast tumors but the gene is uncommonly amplified [19, 20] . Although, less is known about cyclin D3 in BC, there is evidence that cyclin D1 and D3 have nonredundant functions [21, 22] and are differentially expressed in breast and uterine cancers [23, 24] .
To assess whether cell cycle deregulation contributes to solely E 2 -induced ACI rat mammary oncogenesis, we have systematically analyzed D1 and D3 protein and mRNA expression levels in pre-malignant lesions during E 2 oncogenesis and compared them to mammary glands from normal cycling rats and primary invasive ductal BCs.
Materials and Methods

Animals and Treatment
Intact female ACI rats were purchased from Harlan Sprague Dawley Inc. (Indianapolis, IN) at 6-8 weeks of age. They were housed individually in an AAALAC-accredited facility under controlled temperature, humidity, 12 hr light:12 hr dark cycles, and provided with Teklad Rodent Diet 8604, and tap water ad libitum. The animal studies were carried out in adherence to the guidelines established in the Guide for the Care and Use of Laboratory Animals (US Department of Health and Human Resources, NIH, 1985) . The rats were acclimated for at least one week prior to treatment, and then randomly distributed into four groups of E 2 -treated and corresponding equal number of age-matched untreated control groups with 6 to 10 animals per group. All rats in the treated groups received a single pellet containing either 20 mg cholesterol alone or 3 mg of E 2 plus 17 mg of cholesterol (Hormone Pellet Press, Leawood, KS) implanted in the shoulder region for 3.0-6.0 months as previously described [6] . The E 2 -treated groups were killed after 3.0, 4.0, 5.0, or 6.0 months (tumor bearing). Over the treatment period, the E 2 serum levels were 123.5 +/-4.8 pg/ml (3.0 months) and 121.8 +/-3.0 pg/ml (6.0 months), similar to values reported previously [5] . At the end of each individual treatment period, the rats were killed by decapitation, subjected to macroscopic examination, and the presence MGTs, both number and location was recorded. The abdominal-inguinal mammary glands and the MGTs, freed of connective and necrotic tissue, respectively, were quickly removed. Portions of these tissues were immediately frozen in liquid nitrogen and stored at -80 o C for later analysis, while others were fixed in 10% buffered formalin, followed by a rapid paraffin-embedding process. 
Classification of Lesions
For histopathological evaluation, mammary gland sections were prepared from paraffinembedded blocks and stained with hematoxylin and eosin (H&E). The mammary gland lesions after E 2 -treatment were identified as follows: small focal dysplasia, commonly seen at 3.0-to 3.6-months, contained cells with large, light staining nuclei, and prominent nucleoli with or without secondary lumens. Large dysplastic foci, observed between 3.6 to 4.0 months, were similar to the designation for human atypical ductal hyperplasia (ADH) [25] , and were characterized by large, evenly spaced nuclei arranged in a regular pattern which occasionally also formed a rosette-like pattern around more evenly shaped secondary lumens. DCIS, also present after 4.0 months of E 2 -treatment, exhibited features described for ADH, but displayed more regular punched-out secondary lumens, with a cross sectional diameter of > 2 mm. The majority of the DCISs seen were characterized as cribiform. Lower frequencies of comedo, papillary, and solid-type DCISs were also observed. MGTs were recognized when atypical cells, similar to those observed in DCIS, were seen invading the surrounding stroma.
Western blot
Mammary glands were homogenized in lysis buffer containing 50 mM Tris-HCl pH 7.4, 0.2 M NaCl, 2 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.5 mM Na 3 VO 4 , 20 mM tetra Napyrophosphate, 1 mM PMSF, 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mM DTT.
The supernatant fractions were collected and their protein content determined with BCA reagents (Pierce, Rockford, IL). Proteins were separated by gel electrophoresis on 9 PAGEr Gold Precast Gels (Cambrex Bio Science Rockland, Inc., Rockland, ME) and transferred to a nitrocellulose membrane. Primary antibodies against ERα (6F11), cyclin D1, [cdk2 (2B6) (Lab Vision Corporation, Fremont, CA)], PR, [cdk4 (C22) (Santa Cruz)], or cyclin D3 were the same as those used for immunohistochemistry, and the following were incubated overnight at 4ºC. Appropriate secondary antibodies were incubated for 2 h and protein expression was visualized with ECL chemiluminescence (Amersham Biosciences, Piscataway, NJ). For these studies, age-matched untreated control rats, and E 2 -treated for 4.0 and 6.0 months were used.
Immunoprecipitation and Kinase Assay of Primary E 2 -induced Mammary Tumors
Proteins were extracted as described for western blotting. Aliquots, 500 µg of total protein, were briefly precleared with appropriate normal IgG and A/G-agarose (Santa Cruz). Protein extracts were then incubated for 2.0 h with 1 µg of the same antibodies used for western blot for cyclin D1, D3, and cdk4, followed by 2.0 h incubation with 30 µL A/G agarose slurry.
Normal IgG was used as a negative control.
Immunoprecipitated complexes were washed several times with PBS and immediately used for Rb-kinase assays (Upstate USA, Inc., Charlottesville, VA) following the manufacturer standard protocol. Briefly, immunoprecipitates were incubated for 30 min, at 30°C with assay dilution buffer (20 mM MOPS; 25 mM β-glycerol phosphate, pH 7.2;
Phosphor Imager (Amersham). For these studies, age-matched untreated control rats and E 2 -treated for 6.0 months (tumor tissue only) were used.
Reverse Transcriptase PCR (RT-PCR)
All reagents for RT-PCR were purchased from Invitrogen Corp., Carlsbad, CA. 
DNA isolation and Quantitative Real-time PCR (Q-PCR) for gene amplification
DNA from mammary glands from age-matched, untreated, controls and from E 2 -treated for 4.0 months, and tumor tissue from rats treated for 6.0 months was extracted by the LiCl of Gemmell and Akiyama [26] . 74 bp amplicon). The baseline was set automatically and the threshold Ct value was measured during the exponential phase of the amplification. Each assay was performed in triplicate.
Statistical analyses
One way ANOVA with Dunn or Tukey post-hoc tests were used for statistical evaluation.
Values were expressed as the mean ± SE. Statistical significance was assumed when p < 0.05 was obtained.
Results
Western blot analysis of cyclin D1, D3, and cdk4 protein expression during mammary oncogenesis
Cyclin D1 and D3 protein expression was assessed in mammary glands from 4.0-month E 2 -treated, primary
MGTs, and age-matched untreated controls. After 4.0 months of E 2 treatment, the protein expression of cyclin D1 rose 3.0-fold, and it was statistically significant compared to age-matched untreated cycling mammary glands ( Figure   1 ). A significant 24.8-fold increase, however, was observed in primary MGTs. Cyclin D3 expression was essentially undetected after 4.0 months of E 2 treatment, but significantly rose 9.0-fold in MGTs when compared to age-matched untreated mammary glands. A significant 3.1-fold elevation in the expression of cdk4, an associated kinase for cyclin D1 and D3, was also detected in MGTs when compared to the evidently substantial levels already present in untreated age-matched cycling mammary glands (Fig. 1A) .
Cyclin D1/D3 expression in age-matched untreated mammary glands and primary breast tumors
Untreated age-matched mammary glands from virgin cycling rats exhibited a limited number of lobular units containing small terminal ducts surrounded by occasional Figure 1 ductules or acini. Cyclin D1 protein expression was detected along the cells in the inner luminal epithelial layer ( Fig. 2A) , but cyclin D3 expression was uncommonly seen in these cells (Fig. 2B ). E 2 -induced MGTs were characterized by cells uniformly showing nuclear enlargement, hyperchromasia, pleomorphism, and prominent nucleoli. Both cyclin D1 and cyclin D3 were consistently over-expressed in E 2 -induced primary MGTs (Fig. 2C, D) relative to age-matched untreated mammary glands.
ERα, PR and cyclin D1/D3 expression in pre-malignant mammary lesions
Female ACI rats, treated with E 2 for 3.0-6.0 months showed marked lobular-alveolar hyperplasia, consisting of acini lined by epithelial cells with small nuclei and some lactational changes (Fig. 3A) . Focal dysplasias consisted of cells with large pale nuclei compared to those in adjacent hyperplasias (Fig. 3F) .
The most common histopathologic type of DCIS seen was cribiform (Fig. 3K) . A few of the cell nuclei were giant in size and consistently found in focal dysplasias, DCISs, and primary MGTs during different periods of E 2 treatment (Fig. 3O, arrows) . Serial sections of E 2 -induced hyperplasia, focal dysplasia, and DCIS were examined for the expression of ERα, PR, cyclin D1, and D3 (Fig. 3) . 
Cyclin D1 and D3 immunoprecipation and kinase assay
To determine whether the elevated protein expression of cyclins D1 and D3 was functionally active in MGTs, co-immunoprecipitation and kinase assays were performed using Rb as a substrate. Since a prerequisite to the formation of a functional cyclin/cdk A direct association between cdk4 and cyclins D1 or D3 was observed (Fig. 5A ). As expected, neither cyclin D1 nor D3 formed complexes with cdk2 (Fig. 5A ). To further assess the functionality of cyclin/cdk complexes, immunoprecipitated cyclins D1 and D3 proteins were subjected to kinase assays utilizing [ further rise, 2.9-fold, in MGTs, compared to age-matched untreated cycling mammary glands. In primary MGTs, cyclin D3 mRNA levels also exhibited a significant, but more modest, 1.4-fold, increase when compared to age-matched untreated mammary glands.
Q-PCR analysis of cyclin D1 and D3 genes
To assess gene copy number, Q-PCR analysis of cyclins D1 and D3 genomic DNA was performed on ten age-matched untreated mammary glands and an equal number of reported [7] .
Discussion
Cell cycle deregulation, particularly over-expressed cyclin D, has been implicated in various human cancers, including invasive ductal BC [27] . Cyclin D1 protein is overexpressed in more than 50% of human BCs [28] and has been frequently detected early in breast pre-neoplasias [29] . The 11q13 amplicon, in which cyclin D1 resides, has been shown to be amplified in a modest number of primary human BCs [30] and in several human BC cell lines [31] [32] [33] . Much less is known about cyclin D3 in human BC, however, its over-expression in high grade human breast tumors has been reported [34] . MGTs develop in transgenic mice over-expressing cyclin D1 [35] , while cyclin D3
over-expression leads to squamous cell carcinomas in mouse mammary glands [36] .
Taken together, these findings support an oncogenic role for cyclins D1 and D3, but their effects may involve different pathways.
It is evident that the elevated levels of cyclin D1 observed in mammary glands during E 2 -induced oncogenesis in the ACI rat may provide a distinct growth advantage to cells undergoing focal dysplasia, DCIS, and MGT development. A number of studies have reported that normal resting human breast, ductal hyperplasia, and atypical ductal hyperplasia (ADH) exhibit very weak levels of cyclin D1 expression [37, 38] . Similarly, in the ACI rat, the normal cycling mammary gland expresses low levels of cyclin D1, but in E 2 -elicited hyperplasia higher levels of this cyclin were detected. This is likely due to the sustained E 2 serum levels in these treated rats. In relation to cyclin D1 expression, moderate to strong positive nuclear staining has been reported in 39.4% of the cells contained in human ADH/dysplasia [29] , and in 59% of the cells within human DCISs and invasive ductal BCs [33, 37] . Cyclin D3 expression has been detected in 10% of human BCs [39] ; however, its expression in early pre-malignant stages has not been assessed. The over-expression of both cyclin D1 and D3 in early stages of E 2 -induced breast oncogenesis in ACI rats, reported herein, suggests their involvement during incipient stages of MGT development. These data are consistent with a report demonstrating that of the total number of specimens analyzed, 75% showed elevated cyclin D1 mRNA in low grade DCISs and 87% in comedo-type DCISs [37] . Unlike ERα, PR, and cyclin D1, the nuclear expression of cyclin D3 in normal hyperplasia was weak and detected in only few hyperplastic cells. With continued E 2 treatment, cyclin D3 over-expression was confined largely to focal dysplasias, DCISs, and primary MGTs, indicative of its selective expression, likely driven by the sustained E 2 exposure.
Consequently, the early over-expression of cyclin D3 may also have a distinctive role in E 2 -induced rat mammary oncogenesis. Interestingly, hepatocytes and human breast epithelial cells, designed to over-express cyclin D1, resulted in centrosome amplification [40] . However, it is unclear whether this is a direct or indirect effect mediated by a downstream alteration occurring as a result of continued cell cycle progression.
Interestingly, hepatocytes and human breast epithelial cells, designed to over-express cyclin D1, exhibited centrosome amplification [40] . However, it is unclear whether this is a direct or indirect effect mediated by a downstream alteration occurring later in cell cycle progression.
In the chemical carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP)-induced rat BC model, the resulting MGTs did not over-express cyclin D3 [41] .
This illustrates differences between chemical carcinogen-versus estrogen-induced murine mammary oncogenesis. Indeed, differences have been also reported in relation to aneuploid frequencies in MGTs induced by synthetic and environmental chemical carcinogens (<15%) and solely estrogen-induced MGTs (>84%) [7] ; the MGTs generated by chemical carcinogens were highly diploid, whereas E 2 -induced MGTs were found to be highly aneuploid, a feature that is characteristic of both human DCISs and invasive ductal BCs [40] .
Compared to a moderate rise in cyclin D1 mRNA, only a modest increase in mRNA cyclin D3 expression was detected. This finding suggests that the elevated levels of cyclin D3 in particular may be in part due to post-translational stabilization of the protein. Similar results have been reported for cyclin D3 in a human uterine sarcoma cell line [42] , as well as in primary human BCs [34] . While the rise in cdk4
protein does not coincide with the much greater elevation in cyclin D1/D3 protein in E 2 -induced MGTs, there is growing evidence that the D-type cyclins have cdk-independent functions [43, 44] . For instance, cyclin D1 forms physical associations with more than 30 transcription factors/co-regulators, such as DMP1 (cyclin D1-interacting myb-like protein), C/EBPβ, and STAT3 (signal transducers and activation of transcription), as well as several nuclear receptors, including the estrogen receptor α (ERα) [45, 46] . In this instance, cyclin D1 binds with p300/CBP-associated factor and potentiates activation of ERα [47] .
Our observation that cyclin D1 and D3 genes were not amplified in E 2 -induced ACI rat MGTs is consistent with either a relatively low or undetected amplification levels of these genes (0-16%) in human BC, frequently associated with an elevated level of ERα expression [20] . However, cyclin D1 gene amplification may not be required to 
